07:00 , Jul 14, 2014 |  BC Week In Review  |  Company News

Takeda Pharmaceutical Co. Ltd cardiovascular news

Takeda said law firm Jones Day, a third-party investigator, did not find evidence that the pharma falsified or fabricated data or had direct involvement in statistical analysis work related to the investigator-initiated Phase III CASE-J...
07:00 , Apr 14, 2014 |  BC Week In Review  |  Company News

Takeda cardiovascular news

Takeda said the Japan Pharmaceutical Manufacturers Association (JPMA) imposed sanctions on the company for promotional activities regarding the investigator-initiated Phase III CASE-J trial of the pharma's Blopress candesartan cilexetil for hypertension. Takeda was suspended...
07:00 , Mar 17, 2014 |  BC Week In Review  |  Company News

Takeda cardiovascular news

Takeda appointed law firm Jones Day as a third-party investigator in response to issues raised by the media regarding the investigator initiated Phase III CASE-J trial of the pharma's hypertension drug Blopress candesartan cilexetil....
08:00 , Dec 3, 2012 |  BC Week In Review  |  Company News

Dainippon Sumitomo, Shionogi sales and marketing update

Dainippon and partner Shionogi plan to launch hypertension drug Aimix amlodipine besilate/irbesartan in Japan on Dec. 19. The product is an oral combination of amlodipine besilate, a calcium channel blocker, and irbesartan, an...
07:00 , Oct 8, 2012 |  BC Week In Review  |  Clinical News

Aimix amlodipine besilate/irbesartan regulatory update

Dainippon said Japan's Ministry of Health, Labor and Welfare (MHLW) approved Aimix amlodipine besilate/irbesartan to treat hypertension. Dainippon and Shionogi & Co. Ltd. (Tokyo:4507; Osaka:4507, Osaka, Japan) will co-market the product in Japan under...
07:00 , Jul 2, 2012 |  BC Week In Review  |  Clinical News

Amlodin amlodipine besilate regulatory update

Dainippon said Japan's Ministry of Health, Labor and Welfare (MHLW) approved an expanded label for Amlodin amlodipine besilate to treat hypertension to include pediatric patients >6 years. The calcium channel blocker is already approved...
08:00 , Dec 5, 2011 |  BC Week In Review  |  Clinical News

Amlodipine besilate/irbesartan regulatory update

Dainippon submitted a regulatory application to Japan's Ministry of Health, Labor and Welfare (MHLW) for amlodipine besilate/irbesartan to treat hypertension. The product is an oral combination of amlodipine besilate, a calcium channel blocker, and...